The latest: Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (2196.HK; 600196.SH) said Sunday its revenue increased 1.7% year-on-year to 10.27 billion yuan ($1.4 billion) in the third quarter, as measured using Chinese GAAP. But its net profit fell 16.2% to 907 million yuan.

Looking up: Despite the profit decline, the company’s net cash flow from operating activities increased 3.4% year-over-year to 1.35 billion yuan in the latest quarter.

Take Note: The company’s revenue grew 26% in the first half of this year to 2.13 billion yuan, much higher than the 1.7% increase in the third quarter, meaning its business slowed significantly in the latest period.

Digging Deeper: Fosun Pharm is a diversified drug company whose portfolio includes pharmaceutical, medical equipment and healthcare services. Of its 21.3 billion yuan in first-half revenue, about 67% came from the pharmaceutical manufacturing business, while medical devices and medical diagnostic and healthcare services accounted for about 19% and 14%, respectively. The company said it is aiming to build a regional healthcare model and health services industry chain. As part of that, it spent nearly 1 billion yuan to acquire 60% of one of the largest private oncology specialty medical centers in Singapore in June.

Market Reaction: Fosun Pharmaceutical shares rose 8.1% on Monday morning, and were up 3.9% at HK$20.1 at the midday break. The stock currently trades near the lower end of its 52-week range.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

From Delhi risks to a domestic dairy bust

Some Chinese companies are navigating geopolitical headwinds that are pushing them out of India, and others are adapting to a maturing domestic consumer market where even staples like infant formula…
Yan Palace makes bird's nest products

Yan Palace swoops back to profit growth

China’s largest edible bird’s nest brand said its profit rose 20% to 35% in the first half of 2025, returning to bottom line growth despite pressure on revenue Key Takeaways:…